A B S T R A C T In eight patients with sickle cell anemia, weekly extracorporeal carbamylation of about 20% of the circulating red cell mass was carried out for 2 yr or longer. At each visit, a mean of 1.3±0.2 mol of cyanate were incorporated per mole of hemoglobin in the carbamylated erythrocytes. Within 3 mo, a stable level of about 35-50%' of the circulating erythrocytes was carbamylated. This quantity and degree of hemoglobin carbamylation produced a decrease in mean whole blood Pw0 from 33 to 26 mm Hg. During the first 3 mo of carbamylation, the mean hemoglobin increased from 6.4 to 9.1 g/100 ml, while mean absolute reticulocytes decreased by 58% and circulating irreversibly sickled erythrocytes decreased by 65%. The mean red cell life span increased from 13 days before treatment to 21.6 days after 3 mo of carbamylation. Beyond the 3rd mo of carbamylation, blood P50, hemoglobin, and reticulocytes remained quite stable. No toxic effects of extracorporeal carbamylation of erythrocytes were noted. The capacity of blood to release oxygen at 30 mm Hg Po2 increased from 4.3 to 5.0 cm3/100 ml blood during carbamylation.
INTRODUCTION
Incubation of erythrocytes from patients with sickle cell anemia (Hb SS)' with cyanate (NCO) or carbamyl phosphate inhibits in vitro sickling upon deoxygenation of these cells (1, 2) . NCO and carbamyl phosphate react irreversibly with the amino-terminal valine residues of hemoglobin in a reaction termed carbamylation (1) (2) (3) (4) (5) (6) . Carbamylation increases the oxygen affinity (7) (8) (9) and inhibits the gelation of sickle cell hemoglobin (Hb S) (1, 4) . Because of the increase in oxygen affinity of carbamylated Hb SS erythrocytes, greater saturation of hemoglobin with oxygen occurs at physiological oxygen tensions. The increase in oxygen affinity produced by carbamylation appears to be the major mechanism responsible for the antisickling effect of NCO (4, (7) (8) (9) .
In vitro carbamylation of Hb SS erythrocytes prolongs the survival of such erythrocytes returned to the 'Abbreviations uised in this paper: DFP, diisopropylfluorophosphate; Hb S, sickle hemoglobin; Hb patient (6, 7, (10) (11) (12) . This observation suggests that the antisickling effects observed in vitro persist in vivo and also that there is no overall deleterious effect of incubating erythrocytes with NCO or carbamyl phosphate. With this information, pilot studies employing repeated extracorporeal red cell carbamylation with sodium cyanate were undertaken in informed symptomatic patients with sickle cell anemia at this institution in 1972. This report describes hematologic and clinical responses observed in these patients. METHODS 10 patients with sickle cell anemia participated in this study.
Pertinent base-line hematologic and clinical information on each patient is presented in Table I . All of the patients were examined weekly for 2-3 mo before beginning weekly carbamylation. During this period, control values for hemoglobin, reticulocytes, irreversibly sickled cells (ISC), and whole blood Pm (oxygen tension at which (HbO2/Hb) = l or 37°C, pH 7.40) were established for each patient. Reticulocyte and ISC counts are reported as percent of circulating erythrocytes (uncorrected).
Criteria for selection of patients for this study were: (a) frequent, severe painful manifestations with at least two hospitalizations for acute painful crises in the previous 6 mo (patient 1-7, 9); and (b) chronic indolent malleolar ulcerations interfering with ambulation (patients 8-10).
Patients 3 and 8 had sustained permanent neurological damage during adolescence, resulting in hemiparesis. The neurological deficit became more pronounced in both patients during more pronounced anemia and cardiac decompensation.
Seven of the patients had been followed by physicians involved in this study for 2-12 yr before entering this study. Three of the patients were referred to this center for participation in the study; medical records from referring centers were reviewed in each to ascertain the frequency of painful crises requiring hospitalization for management.
The technique employed to carbamylate erythrocytes at each weekly visit was as follows. After placement of a no. 19 scalp vein needle in a forearm vein, 500 ml of blood was collected by gravity in a plastic bag containing 1,500 U of heparin and 100% 02. After centrifugation, the plasma was reinfused while the red cells were diluted to a hematocrit of 50% with 0.15 M NaCl, after which a 0.15 M solution of NaNCO, recrystallized from 65% ethanol and forced through 0.22 ,um Millipore filters,2 was added to the red cells to a final concentration of 30 mM. 50 cm' of 95% 02-5% C02 was added to the blood bag to maintain greater than 95% oxygenation of the hemoglobin and a reproducible pH (7. 45+0.05 at 37°C) during incubation. Under these conditions, 1.2±0.4 mol of ["4C]NCO were incorporated per tetrameric mole of hemoglobin after a 1-h incubation at 37°C. The red cells were washed twice with 0.15 M NaCl and reinfused. A second 500-ml unit of blood drawn just before the reinfusion of the first unit of carbamylated cells was handled similarly. The procedure was repeated weekly unless whole blood P5o decreased to less than 24 mm Hg or the hematocrit exceeded 32%; in these circumstances carbamylation was carried out biweekly.
At each weekly visit, hemoglobin, hematocrit, white blood count with differential, platelet count, reticulocyte, ISC count, and whole blood P.> were determined. Whole blood P.l was measured with the IL 217 blood gas system" to achieve progressive stepwise deoxygenation of the hemoglobin. ISC counts were determined on blood equilibrated with 95% O5-5% C02 by criteria previously described (13 Table  III. A graphic presentation of similar data for the first 24 mo of carbamylation on the eight patients who underwent long-term carbamylation is shown in Fig. 1 . Hemoglobin rose progressively and reticulocytes, ISC, and P60 decreased progressively in all patients during the first 3 mo of carbamylation. By the 3rd mo of carbamylation, whole blood P5. decreased from a mean value of 33 to 26 mm Hg, reticulocytes and ISC decreased from means of 22 and 20 to 11 and 7%, respectively, and mean hemoglobin rose from 6.7 to 8.8 g/100 ml. Absolute decreases in reticulocytes and ISC of 58 and 65%, respectively, occurred. Hemoglobin, reticulocyte, ISC, and Pmo values remained stable beyond the 3rd month in those eight patients who continued carbamylation. The hemoglobin increased from 6. ml before treatment to 9.8 g/100 ml after 9 mo of carbamylation in these eight patients. Direct measurements of MLS demonstrated prolongation of the MLS of erythrocytes after carbamylation. Before beginning weekly carbamylation, the mean MLS of untreated erythrocytes for all 10 patients was 13.2 days (range 8.4-16.8 days). The simultaneously measured mean MLS of erythrocytes containing 1.3±0.4 mol of NCO/mol of hemoglobin [estimated by 14NCO incorporation in separate aliquots of blood] was 25 days (columns 1 and 2, respectively, Fig. 2 ). In a given patient, prolongation of the MLS of carbamylated erythrocytes was related overall to the degree of hemoglobin carbamylation obtained (Table IV) . In analyzing the actual prolongation of MLS of carbamylated erythrocytes among the 10 patients, the incorporation of a mean of 1.3 mol of NCO/mol of hemoglobin roughly doubled the MLS value (Fig. 2) . In five patients a repeat dual survival study was carried out after 3 In addition, the increase in hemoglobin and concomitant decrease in reticulocytes observed in all patients also suggests decreased destruction rather than increased production of erythrocytes in these patients during carbamylation.
Worsening of the hemolytic anemia invariably occurs upon stopping repeated carbamylation. The hematological responses of two patients during and after 12 wk of carbamylation are presented in Figs. 3 (patient 7) and 4 (patient 6). Both patients demonstrated an improvement in their anemia during carbamylation and return of hemoglobin and reticulocytes to pretreatment levels within 5-8 wk after stopping carbamylation. It is important to note the slower increase in hemoglobin during carbamylation in patient 7, who presented both a more severe but stable anemia and shorter MLC than patient 6 (MLS 9.1 vs. 15.4 days, respectively). During the initial visits, only 130-140 ml of erythrocytes were carbamylated weekly in patient 7, as opposed to 180-200 ml of erythrocytes in patient 6, because of the more severe anemia in patient 7. In addition the MLS of carbamylated erythrocytes was 15.6 days in patient 7 and 27 days in patient 6.
Levels of circulating carbamylated hemoglobin. In six patients maintained on weekly carbamylation for 6 mo, hemoglobin carbamylation of circulating erythro- fusion of carbamylated cells at that visit (Table V) . All six patients experienced significantly fewer crises during the 24 mo of carbamylation; a total of 14 admissions for painful crises occurred during carbamylation. The average duration for each crisis during carbamylation was 5 days. As before carbamylation, the frequency of crises in patient 1 grossly exceeded that of the other patients. Only 1 of the 14 crises appeared to be a spontaneous crisis. Respiratory and urinary tract infections ushered in 10 and 3 of the crises, respectively. The rarity of spontaneous crises during carbamylation was striking; the total number of induced crises during carbamylation was one-half that before carbamylation (13 versus 27).
A second major objective clinical response noted during carbamylation was the complete healing of chronic malleolar ulcerations in three patients (8) (9) (10) . Bilateral, painful ulcerations accompanied by adjacent induration, brawny edema, and recurrent episodes of superficial thrombophlebitis of surrounding areas were present for 2 yr in patient 8, for 4 yr in patient 9, and for 6 yr in patient 10. Transfusions followed by a skin graft in 1969 were of only temporary benfit in patient 10. Local supportive measures, consisting of twicedaily saline soaks followed by dilute hydrogen peroxide debridement, were continued before and during carbamylation. The induration and tenderness of the area adjacent to the ulcerations disappeared after 2-3 mo of carbamylation after which gradual circumferential closure of the open ulcerations occurred. After 5-8 mo of carbamylation (as depicted in Fig. 5 ), irregular areas of depigmentation of skin persisted as the only residual of the previous ulcerations in the three patients.
We have had the opportunity to follow the clinical response of patient 1 upon stopping carbamylation for 11 mo in 1975. Gaining ready access to the venous circulation was a formidable technical problem throughout the previous 2 yr of carbamylation in this patient. In January 1975, a bovine carotid artery arteriovenous fistula was created in the forearm, but it functioned only temporarily. The consequent loss of forearm veins after this unsuccessful procedure made phlebotomies for red cell carbamylation extremely difficult for several months thereafter. Carbamylation of 10-20% Untoward effects of long-term extracorporeal carbamylation of sickle erythrocytes. We have encountered no evidence of NCO toxicity in patients who have been maintained on weekly red cell carbamylation for up to 3 yr. Systemic toxicity resulting from cyanate administration at the weekly visit would be extremely unlikely because of (a) the irreversibility of the carbamylation reaction, (b) preferential red cell incubation (plasma removed before incubation), and (c) the removal of free NCO by saline washing before reinfusion of the carbamylated erythrocytes.
Several potential problems associated with the phlebotomy exist. Hypotension due to the phlebotomy, clotting, and contamination of the blood during in vitro manipulation are ever-present concerns. Of these potential problems, we have encountered only one. On two occasions 1 pint of blood was lost due to faulty plastic bags, which leaked during centrifugation. Saline infusion before initiating the phlebotomy and reinfusion of the plasma shortly after its collection effectively prevent any hypotension.
Carbamylation increases the affinity of hemoglobin for oxygen; the increase in oxygen affinity depends upon the degree of hemoglobin carbamylation. The increase in oxygen affinity noted during carbamylation, unless accompanied by increases in hemoglobin levels, will decrease the capacity of blood to release oxygen to tissues. We examined the alterations in the oxygen release capacity of blood during carbamylation. By knowing blood hemoglobin and P50 values, and assuming uniform equili- Data based upon 25% increase in the pretreatment hemoglobin of 6.5 g/100 ml.
bration of arterial and mixed venous blood at oxygen pressures of 90 and 30 mm Hg, respectively, one can calculate the quantity of oxygen that can be released from blood equilibrated under these conditions (oxygen release capacity). Table VII (parts A and B) summarizes the alterations in the mean oxygen release capacity of blood in response to carbamylation in the eight patients who underwent long-term carbamylation. Because the hemoglobin level increased progressively as the P50 of blood decreased, the oxygen release capacity of these eight patients actually increased during carbamylation.
It is important to note the minimum P60 during carbamylation was 25 mm Hg. DISCUSSION The ideal mode of approach for carbamylating sickle erythrocytes would be the daily oral administration of a nontoxic reagent which reacted selectively with only the sickle-cell hemoglobin. Unfortunately, such a reagent is currently not available. Widespread protein carbamylation occurs in the body after oral or parenteral administration of sodium cyanate (17) (18) (19) . Toxicity arising from this indiscriminant protein carbamylation, particularly a dose-dependent polyneuropathy (20, 21) , has in essence stopped further clinical trials with orally administered NCO. Our reservations concerning the oral use of sodium cyanate in patients led us to pursue the approach of repeated extracorporeal carbamylation of sickle erythrocytes to avoid systemic toxicity resulting from indiscriminant protein carbamylation.
The studies described in this report demonstrate a significant improvement in the hemolytic anemia of sicklemic patients in whom a mean of 1.3 mol of NCO was incorporated per mole of hemoglobin in about 20%
of the circulating red cell mass on a weekly basis. A steady state was reached by the 3rd mo of weekly carbamylation, wherein 35-50% of the circulating erythrocytes were carbamylated. Mean hemoglobin increased 40% during the first 3 mo of weekly carbamylation. Coincident with the increases in hemoglobin, circulating reticulocytes decreased; mean absolute reticulocytes decreased by 58% by the 3rd mo. In addition, MLS increased after 3 mo of carbamylation. The improvement in the hemolytic anemia observed during carbamylation thus appears to result more from decreased destruction than from increased production of erythrocytes. Upon stopping carbamylation, reticulocytes promptly increased while hemoglobin values decreased, both returning to pretreatment levels. This observation lends additional support to the view that decreased destruction of erythrocytes during carbamylation was responsible for the improvement in the anemia.
In The findings of a separate study (22, 23) employing extracorporeal red cell carbamylation in four sicklemic patients were discordant with the observations of this report in two critical areas. During 6 mo of treatment in the separate study no decrease in the frequency or severity of painful episodes were noted in three of the four patients. Second, during carbamylation reticulocytes increased by an average of 22% over control period values, red cell production as measured by erythron iron turnover was 17% greater than during the pretreatment period, and approximate twofold elevations of erythropoeitin levels were noted after a carbamylation cluster (23). The protocol described for this study also differed with that reported herein in two important aspects. First, red cell carbamylation was carried out in clusters, usually one unit of blood a day until cyanation had reached two moles per mole of hemoglobin in the blood of the patient and until the P60 had dropped to about 20 mm of mercury. When the P50 rose to 24 to 26 mm of mercury the carbamylation series was repeated (23) . Second, the degree of hemoglobin carbamylation achieved during incubation was much greater, averaging 2.34 mol of cyanate per mole of hemoglobin as opposed to 1.3 mol obtained with our protocol. An additional potentially important difference during the incubation of red cells with NaNCO was that partially oxygenated erythrocytes were incubated at a lower pH (acid citrate dextrose anticoagulant) and at 4°C for 24 h. More alpha chain, less beta chain amino-terminal valine carbamylation and possibly greater epsilon amino-lysine carbamylation of hemoglobin could be anticipated under these latter incubation conditions (4, 5).
A logical explanation exists for the discordant finding of increased red cell production during carbamylation observed in the Seattle study. Because of the extensive hemoglobin carbamylation and the carbamylation schedule (cluster approach) utilized, the ability of erythrocytes to release oxygen to tissues during carbamylation was significantly impaired in the Seattle study. It is informative to compare the alterations in the oxygen release capacity of blood during carbamylation in our protocol with alterations that would occur after a cluster of carbamylation of circulating erythrocytes (Table VII). Had we utilized the Seattle approach of daily (cluster) blood carbamylation until blood P60 decreased to 20 mm Hg, the oxygen release capacity of blood would have decreased to approximately half of the pretreatment value after a cluster series, if the hemoglobin increased by the 25% reported (23) (part D, Table VII ). With a decrease in blood P5M to 20 mm Hg, the hemoglobin level would have to increase from 6.5 to 17.2 g/lOO ml to maintain equal oxygen release capacity after carbamylation. In view of these considerations, it is not surprising that reticulocytes and erythrocyte iron turnover increased in response to carbamylation in the Seattle study (23) .
It is tempting to speculate that the lack of clinical improvement during carbamylation in the Seattle study also was in part related to the carbamylation protocol. Because of the inordinate oxygen affinity of the carbamylated erythrocytes, enhanced deoxygenation of untreated erythrocytes would be necessary to meet tissue oxygen requirements. Enhanced deoxygenation would predispose the untreated erythrocytes to exaggerated sickling, offsetting any clinical benefit afforded by carbamylation.
The hematologic improvement, the healing of chronic sickle ulcerations of skin, and the decrease in the frequency of severe painful crises noted during carbamylation in this study offer sufficient promise to justify the development of more efficient and more physiological techniques for extracorporeal carbamylation of sickle erythrocytes. In considering future applications of extracorporeal red cell carbamylation in the management of patients with sickle cell anemia, it is essential that the quantity and quality (degree) of hemoglobin carbamylation be carefully controlled to avoid undesirable side effects, such as major decreases in the oxygen release capacity of blood. A potentially useful technique for uniform carbamylation of the entire circulating red cell mass in several hours is hemodialysis-carbamylation. Cyanate can be continuously added to blood, and after incubation, unreacted cyanate can be removed from the blood before its return to the patient by dialysis. During each carbamylation session, the oxygen affinity of blood increases acutely in proportion to the degree of hemo-globin carbamylation. The increase in oxygen affinity, unaccompanied by an increase in hemoglobin during the carbamylation session, decreases the oxygen release capacity of blood (part C, Table VII ). Until hemoglobin levels increase in the severely anemic patient, the degree of carbamylation must be limited to avoid serious embarrassment to tissue oxygenation.
Implicit in the data of this presentation are several impor.tant shortcomings of erythrocyte carbamylation as a potential therapy for sickle cell anemia. The degree of inhibition of sickling effected by carbamylation in large measure depends upon the increased oxygen affinity of the carbamylated hemoglobin. Carbamylated sickle erythrocytes will sickle when deoxygenated. Even extensive carbamylation does not restore the life-span of the SS erythrocyte to more than approximately 40-60 days (11, 23) . The inordinate oxygen affinity of extensively carbamylated cells presents new problems to the anemic patient. It may be possible to better utilize sodium cyanate as an antisickling agent in future clinical studies by carrying out more selective hemoglobin chain carbamylation. Carbamylation of the amino-terminal valine residue of the beta chains increases (rather than decreases) oxygen affinity and, more important, increases the minimum concentration of hemoglobin required for gelation (24, 25) . Alpha chain valine carbamylation increases the affinity of hemoglobin for oxygen. More selective beta chain carbamylation may well allow a greater antisickling effect while minimizing the increase in oxygen affinity.
